<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.106131</article-id><article-id pub-id-type="publisher-id">ACM-35865</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200600000_56949306.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  SII/ALB与EGFR基因突变型晚期非小细胞肺癌预后的相关性分析
  Correlation between SII/ALB and the Prognosis of EGFR Gene Mutation in Advanced Non-Small Cell Lung Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>梓聿</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>玲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>袁</surname><given-names>胜利</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属青岛市市立医院肿瘤科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>29</day><month>05</month><year>2020</year></pub-date><volume>10</volume><issue>06</issue><fpage>857</fpage><lpage>863</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    探讨全身免疫–炎症指数/血清白蛋白(SII/ALB)与EGFR基因突变型晚期非小细胞肺癌预后的相关性分析。收集从2013年6月12日至2017年6月31日在青岛市市立医院诊断的EGFR突变型晚期非小细胞肺癌患者71例，患者服用EGFR-TKI前2周内抽取静脉血，收集临床数据。计算患者的SII/ALB值，以中位数将患者分高、低SII/ALB组。两组患者的PFS曲线应用Kaplan-Meier法比较，之后用Log-rank检验分析两组患者PFS的差异。PFS的影响因素通过Cox单因素、多因素回归进行分析，P &lt; 0.05为差异有统计学意义。高SII/ALB组患者的中位无进展生存期(mPFS)为9.2个月，低SII/ALB组患者的mPFS为14.5个月，Kaplan-Meier法显示低SII/ALB组患者的PFS明显优于高SII/ALB组的患者(Log-rank P &lt; 0.001)。3、Cox单因素回归方法分析提示患者的性别、肿瘤分期、EGFR-TKI初治前血清白蛋白和外周血中性粒细胞、淋巴细胞、血小板计数及SII/ALB值对EGFR-TKI治疗的EGFR突变型晚期非小细胞肺癌患者的PFS的影响有意义，均P &lt; 0.05。应用Cox多因素回归方法分析显示肿瘤分期(HR = 4.124, 95% CI: 1.593~10.675; P = 0.004)、外周血淋巴细胞计数(HR = 0.565, 95% CI: 0.290~0.744; P = 0.000)、SII/ALB (HR = 2.472，95% CI: 1.055~5.788; P = 0.037)是应用EGFR-TKI治疗的EGFR突变型晚期非小细胞肺癌患者PFS的独立影响因素。结论：SII/ALB可作为预测EGFR-TKI治疗EGFR敏感突变型晚期非小细胞肺癌患者预后的指标。
    To investigate the correlation between systemic immune-inflammation index/albumin (SII/ALB) and the prognosis of patients with advanced non-small cell lung cancer (NSCLC) with epithelial growth factor receptor (EGFR) gene sensitive mutation. From June 12, 2013 to June 31, 2017, the demographic and clinicopathological characterictics of 71 NSCLC patients with EGFR sensitive mutation in Qingdao Municipal Hospital of Shandong Province were collected. Venous blood was collected from the patients within 2 weeks before the treatment of EGFR tyrosine kinase inhibitor (EGFR-TKI). The data of SII/ALB of the patients were calculated, and the patients were divided into high and low SII/ALB groups by median. The progression-free survival (PFS) curves of the two groups were compared by Kaplan-Meier method, and the differences in PFS between the two groups were analyzed by log-rank test. The influencing factors of PFS were analyzed by univariate and multivariate Cox regression analysis, and P &lt; 0.05 was considered statistically significant. In the high SII/ALB group, the median PFS was 9.2 months, and mPFS of patients in the low SII/ALB group was 14.5 months. Kaplan-Meier method showed that patients in the low SII/ALB group had significantly better PFS than those in the high SII/ALB group (log-rank P &lt; 0.001). Univariate Cox analysis suggested that gender, tumor stage, serum albumin, peripheral blood neutrophil count, lymphocyte count, platelet count and SII/ALB had significant effects on PFS in patients, P&lt;0.05. Multivariate Cox regression analysis showed tumor staging (HR = 4.124, 95% CI: 1.593 - 10.675; P = 0.004), peripheral blood lymphocyte count (HR = 0.565, 95% CI: 0.290 - 0.744; P = 0.000) and SII/ALB (HR = 2.472, 95% CI: 1.055 - 5.788; P = 0.037) were independent factors affecting PFS in advanced NSCLC patients with EGFR-sensitive mutant treated with EGFR-TKI. Conclusions: SII/ALB can be used to predict the prognosis of EGFR-TKI in the treatment of EGFR mutant advanced non-small cell lung cancer. 
  
 
</p></abstract><kwd-group><kwd>非小细胞肺癌，SII/ALB，络氨酸激酶抑制剂，预后, Non-Small Cell Lung Cancer</kwd><kwd> SII/ALB</kwd><kwd> Tyrosine Kinase Inhibitors</kwd><kwd> Prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>SII/ALB与EGFR基因突变型晚期非小细胞肺癌预后的相关性分析<sup> </sup></title><p>王梓聿<sup>*</sup>，李玲，袁胜利<sup>#</sup></p><p>青岛大学附属青岛市市立医院肿瘤科，山东 青岛</p><disp-formula id="hanspub.35865-formula7"><graphic xlink:href="//html.hanspub.org/file/1-1571307x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年5月3日；录用日期：2020年5月22日；发布日期：2020年5月29日</p><disp-formula id="hanspub.35865-formula8"><graphic xlink:href="//html.hanspub.org/file/1-1571307x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>探讨全身免疫–炎症指数/血清白蛋白(SII/ALB)与EGFR基因突变型晚期非小细胞肺癌预后的相关性分析。收集从2013年6月12日至2017年6月31日在青岛市市立医院诊断的EGFR突变型晚期非小细胞肺癌患者71例，患者服用EGFR-TKI前2周内抽取静脉血，收集临床数据。计算患者的SII/ALB值，以中位数将患者分高、低SII/ALB组。两组患者的PFS曲线应用Kaplan-Meier法比较，之后用Log-rank检验分析两组患者PFS的差异。PFS的影响因素通过Cox单因素、多因素回归进行分析，P &lt; 0.05为差异有统计学意义。高SII/ALB组患者的中位无进展生存期(mPFS)为9.2个月，低SII/ALB组患者的mPFS为14.5个月，Kaplan-Meier法显示低SII/ALB组患者的PFS明显优于高SII/ALB组的患者(Log-rank P &lt; 0.001)。3、Cox单因素回归方法分析提示患者的性别、肿瘤分期、EGFR-TKI初治前血清白蛋白和外周血中性粒细胞、淋巴细胞、血小板计数及SII/ALB值对EGFR-TKI治疗的EGFR突变型晚期非小细胞肺癌患者的PFS的影响有意义，均P &lt; 0.05。应用Cox多因素回归方法分析显示肿瘤分期(HR = 4.124, 95% CI: 1.593~10.675; P = 0.004)、外周血淋巴细胞计数(HR = 0.565, 95% CI: 0.290~0.744; P = 0.000)、SII/ALB (HR = 2.472，95% CI: 1.055~5.788; P = 0.037)是应用EGFR-TKI治疗的EGFR突变型晚期非小细胞肺癌患者PFS的独立影响因素。结论：SII/ALB可作为预测EGFR-TKI治疗EGFR敏感突变型晚期非小细胞肺癌患者预后的指标。</p><p>关键词 :非小细胞肺癌，SII/ALB，络氨酸激酶抑制剂，预后</p><disp-formula id="hanspub.35865-formula9"><graphic xlink:href="//html.hanspub.org/file/1-1571307x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-1571307x8_hanspub.png" /> <img src="//html.hanspub.org/file/1-1571307x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>肺癌是全球发病率和死亡率最高的恶性肿瘤 [<xref ref-type="bibr" rid="hanspub.35865-ref1">1</xref>]，根据病理可分为非小细胞肺癌(NSCLC)和小细胞肺癌(SCLC) [<xref ref-type="bibr" rid="hanspub.35865-ref2">2</xref>]。非小细胞肺癌约占所有肺癌的85%，其中70%初诊时已为晚期，导致预后不良 [<xref ref-type="bibr" rid="hanspub.35865-ref3">3</xref>]。基因检测发现表皮生长因子受体(EGFR)基因突变的晚期NSCLC患者应用表皮生长因子受体络氨酸激酶抑制剂(EGFR-TKI)进行靶向治疗，可获得相较于传统化疗更优的生存期和生活质量。有许多因素可能影响这类患者服用EGFR-TKI时的疗效，但目前还没有一个预测此类患者预后的统一指标。阐明影响此类患者对EGFR-TKI的反应因素并建立相对可行的生物标志物来预测EGFR-TKI的疗效至关重要。本研究分析结合了营养状况、炎症反应和免疫状况的指标SII/ALB对应用EGFR-TKI治疗的EGFR突变型晚期非小细胞肺癌患者PFS的影响，以评估治疗前SII/ALB对于该类患者的预后情况的预测价值。</p></sec><sec id="s4"><title>2. 研究对象和方法</title><sec id="s4_1"><title>2.1. 纳入标准</title><p>选取从2013年6月12日至2017年6月31日在山东省青岛市市立医院诊断为EGFR突变(19外显子缺失或21外显子L858R/L861Q突变)的局部晚期(IIIA、B、C期)或有远处转移(IV期)的非小细胞肺癌(腺癌或鳞癌)患者。获得青岛市市立医院伦理委员会批准。所有患者服用EGFR-TKI (吉非替尼250 mg每日口服一次或厄洛替尼150 mg每日口服一次)。患者行EGFR-TKI治疗前2周内进行血常规、肝肾功、凝血常规、肿瘤标志物等相关常规检查，并行胸部增强CT、颅脑CT或MRI，颈部、腹部CT等影像学检查。</p></sec><sec id="s4_2"><title>2.2. 排除标准</title><p>1) 确诊为双原发或多原发肿瘤；2) 严重的心、肝肾功能受损；3) EGFR-TKI治疗前的2周内有感染病史；4) 相关临床数据不完整或无法定期评估疾病进展情况；5) 因非原发肿瘤及其并发症造成死亡。</p></sec><sec id="s4_3"><title>2.3. 检测方法及数据收集</title><p>采集患者EGFR-TKI治疗前2周内的空腹静脉血，血常规应用迈瑞BC-6000分析仪检测，肝肾功应用贝克曼5800分析仪检测，凝血常规应用迈瑞EXC810分析仪检测，肿瘤标志物应用罗氏E601分析仪检测。从青岛市市立医院实验室系统导出患者血常规、肝肾功、凝血常规和肿瘤标志物的检测结果。利用公式SII/ALB = PLT (10<sup>9</sup>/L) &#180; Neu# (10<sup>9</sup>/L)/Lym# (10<sup>9</sup>/L)/ALB (g/L)，计算患者应用EGFR-TKI治疗前的SII/ALB值，PLT、Neu#、Lym#和ALB分别代表血小板计数、中性粒细胞计数、淋巴细胞计数和血清白蛋白 [<xref ref-type="bibr" rid="hanspub.35865-ref4">4</xref>]。根据相应统计学方法分为高SII/ALB和低SII/ALB组。</p></sec><sec id="s4_4"><title>2.4. 随访</title><p>患者预后主要以PFS表示，结局事件为患者疾病进展或原发肿瘤相关性死亡。每6~8周行一次胸部CT评估疾病进展情况，以RECIST1.1为影像学评价标准，以月为单位计算患者从首次服用EGFR-TKI开始，到出现疾病进展或死亡的这时间作为PFS。随访截止到2019年6月31日或发生疾病进展。</p></sec><sec id="s4_5"><title>2.5. 统计学方法</title><p>使用SPSS 25.0和GraphPad Prism5.0进行统计分析。用频数及构成比来表示分类变量，使用χ<sup>2</sup>检验评估SII/ALB与各分类变量之间的关系。两组患者的PFS曲线应用Kaplan-Meier法比较，之后用Log-rank检验分析两组患者PFS的差异。PFS的影响因素通过Cox单因素、多因素回归进行分析，P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1.患者临床数据</title><p>本研究共分析71例EGFR突变型晚期非小细胞肺癌患者的临床数据如下。性别：23例(32.4%)为男性和48例(67.6%)为女性。年龄：30例(42.2%) &#179; 65岁和41例(57.8%) &lt; 65岁。肿瘤分期：23例(32.4%)为III期和48例(67.7%)为IV期。靶向药物种类：27例(38.0%)服用厄洛替尼和44例(62.0%)服用吉非替尼。血清ALB水平：26例(36.7%) &lt; 35 g/L和45例(63.3%) &#179; 35 g/L。外周血Neu#：65例(91.5%) &lt; 6.3 &#180; 10<sup>9</sup>/L和6例(8.5%) &#179; 6.3 &#180; 10<sup>9</sup>/L。外周血Lym#：29例(40.9%) &lt; 1.1 &#180; 10<sup>9</sup>/L和42例(59.1%) &#179; 1.1 &#180; 10<sup>9</sup>/L。外周血PLT：50例(70.4%) &lt; 300 &#180; 10<sup>9</sup>/L和21例(29.6%) &#179; 300 &#180; 10<sup>9</sup>/L (见表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Clinical dat</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >患者特点</th><th align="center" valign="middle" >低SII/ALB组</th><th align="center" valign="middle" >高SII/ALB组</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >(n = 36)</td><td align="center" valign="middle" >(n = 35)</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >8 (22.2%)</td><td align="center" valign="middle" >15 (42.9%)</td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >28 (77.8%)</td><td align="center" valign="middle" >20 (57.1%)</td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;65</td><td align="center" valign="middle" >26 (72.2%)</td><td align="center" valign="middle" >15 (42.9%)</td></tr><tr><td align="center" valign="middle" >&#179;65</td><td align="center" valign="middle" >10 (27.8%)</td><td align="center" valign="middle" >20 (57.1%)</td></tr><tr><td align="center" valign="middle" >肿瘤分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >III期</td><td align="center" valign="middle" >19 (52.8%)</td><td align="center" valign="middle" >4 (11.4%)</td></tr><tr><td align="center" valign="middle" >IV期</td><td align="center" valign="middle" >17 (47.2%)</td><td align="center" valign="middle" >31 (88.6%)</td></tr><tr><td align="center" valign="middle" >靶向药物</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >厄洛替尼</td><td align="center" valign="middle" >13 (36.1%)</td><td align="center" valign="middle" >14 (40.0%)</td></tr><tr><td align="center" valign="middle" >吉非替尼</td><td align="center" valign="middle" >23 (63.9%)</td><td align="center" valign="middle" >21 (60.0%)</td></tr><tr><td align="center" valign="middle" >血清白蛋白ALB (g/L)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;35</td><td align="center" valign="middle" >4 (11.1%)</td><td align="center" valign="middle" >22 (62.9%)</td></tr><tr><td align="center" valign="middle" >&#179;35</td><td align="center" valign="middle" >32 (88.9%)</td><td align="center" valign="middle" >13 (37.1%)</td></tr><tr><td align="center" valign="middle" >中性粒细胞计数(10<sup>9</sup>/L)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;6.3</td><td align="center" valign="middle" >36 (100.0%)</td><td align="center" valign="middle" >29 (82.9%)</td></tr><tr><td align="center" valign="middle" >&#179;6.3</td><td align="center" valign="middle" >0 (0.0%)</td><td align="center" valign="middle" >6 (17.1%)</td></tr><tr><td align="center" valign="middle" >淋巴细胞计数(10<sup>9</sup>/L)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;1.1</td><td align="center" valign="middle" >19 (52.8%)</td><td align="center" valign="middle" >10 (28.6%)</td></tr><tr><td align="center" valign="middle" >&#179;1.1</td><td align="center" valign="middle" >17 (47.2%)</td><td align="center" valign="middle" >25 (71.4%)</td></tr><tr><td align="center" valign="middle" >血小板计数(10<sup>9</sup>/L)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;300</td><td align="center" valign="middle" >33 (91.7%)</td><td align="center" valign="middle" >17 (48.6%)</td></tr><tr><td align="center" valign="middle" >&#179;300</td><td align="center" valign="middle" >3 (8.3%)</td><td align="center" valign="middle" >18 (51.4%)</td></tr></tbody></table></table-wrap><p>表1. 临床数据</p></sec><sec id="s5_2"><title>3.2. SII/ALB与应用EGFR-TKI治疗的晚期非小细胞肺癌患者无进展生存时间的关系</title><p>采用GraphPad Prism5.0绘制应用EGFR-TKI治疗的高、低SII/ALB组EGFR突变型晚期非小细胞肺癌患者的PFS曲线(见图1)，Log-rank法检验PFS差异。结果显示高、低SII/ALB组患者的mPFS分别为9.2、14.5个月，低SII/ALB组患者的PFS明显优于低SII/ALB组患者(Log-rank p &lt; 0.001)。</p><p>图1. 无进展生存期</p></sec><sec id="s5_3"><title>3.3. 应用EGFR-TKI治疗的EGFR突变型晚期非小细胞肺癌患者预后因素分析</title><p>采用Cox单因素分析模型得出应用EGFR-TKI治疗的EGFR突变型晚期非小细胞肺癌患者的性别、肿瘤分期、血清白蛋白和外周血中性粒细、淋巴细胞、血小板计数及SII/ALB值对EGFR-TKI治疗的EGFR突变型非小细胞肺癌患者的PFS的影响有意义，均P &lt; 0.05。多因素分析显示肿瘤分期(HR = 4.124, 95% CI: 1.593~10.675; P = 0.004)、外周血淋巴细胞计数(HR = 0.565, 95% CI: 0.290~0.744; P = 0.000)、SII/ALB (HR = 2.472, 95% CI: 1.055~5.788; P = 0.037)是应用EGFR-TKI治疗的EGFR突变型晚期非小细胞肺癌患者PFS的独立影响因素，且治疗前肿瘤分期为IV期、外周血淋巴细胞计数&lt;1.1 &#215; 10<sup>9</sup>/L以及SII/ALB值&#179;18.30为应用EGFR-TKI治疗的EGFR突变型的晚期非小细胞肺癌患者PFS的独立危险因素(见表2)。</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Cox single factor and multi factor analysi</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" >影响因素</th><th align="center" valign="middle" ></th><th align="center" valign="middle" >PFS单因素</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" >FPS多因素</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >HR</td><td align="center" valign="middle" >95% CI</td><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >HR</td><td align="center" valign="middle" >95% CI</td><td align="center" valign="middle" >P值</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >0.501</td><td align="center" valign="middle" >0.297~0.845</td><td align="center" valign="middle" >0.010</td><td align="center" valign="middle" >1.116</td><td align="center" valign="middle" >0.594~2.095</td><td align="center" valign="middle" >0.733</td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;65</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&#179;65</td><td align="center" valign="middle" >1.446</td><td align="center" valign="middle" >0.890~2.347</td><td align="center" valign="middle" >0.136</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肿瘤分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >III期</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >IV期</td><td align="center" valign="middle" >5.423</td><td align="center" valign="middle" >2.922~10.065</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >4.124</td><td align="center" valign="middle" >1.593~10.675</td><td align="center" valign="middle" >0.004</td></tr><tr><td align="center" valign="middle" >靶向药物</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >厄洛替尼</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >吉非替尼</td><td align="center" valign="middle" >1.007</td><td align="center" valign="middle" >0.620~1.636</td><td align="center" valign="middle" >0.977</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >血清白蛋白(g/L)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;35</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&#179;35</td><td align="center" valign="middle" >0.407</td><td align="center" valign="middle" >0.239~0.693</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >3.567</td><td align="center" valign="middle" >0.549~23.185</td><td align="center" valign="middle" >0.183</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >中性粒细胞计数(10<sup>9</sup>/L)</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >&lt;6.3</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&#179;6.3</td><td align="center" valign="middle" >3.196</td><td align="center" valign="middle" >1.318~7.748</td><td align="center" valign="middle" >0.010</td><td align="center" valign="middle" >3.148</td><td align="center" valign="middle" >0.696~14.236</td><td align="center" valign="middle" >0.136</td></tr><tr><td align="center" valign="middle" >淋巴细胞计数(10<sup>9</sup>/L)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;1.1</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&#179;1.1</td><td align="center" valign="middle" >0.527</td><td align="center" valign="middle" >0.366~0.652</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.565</td><td align="center" valign="middle" >0.290~0.744</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >血小板计数(10<sup>9</sup>/L)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;300</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&#179;300</td><td align="center" valign="middle" >1.942</td><td align="center" valign="middle" >1.128~3.345</td><td align="center" valign="middle" >0.017</td><td align="center" valign="middle" >1.598</td><td align="center" valign="middle" >0.274~9.321</td><td align="center" valign="middle" >0.602</td></tr><tr><td align="center" valign="middle" >SII/ALB</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;18.30</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&#179;18.30</td><td align="center" valign="middle" >3.272</td><td align="center" valign="middle" >1.937~5.528</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >2.472</td><td align="center" valign="middle" >1.055~5.788</td><td align="center" valign="middle" >0.037</td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. Cox单因素及多因素分析表</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>本研究旨在探讨用SII/ALB预测应用EGFR-TKI治疗的EGFR突变型非小细胞肺癌患者预后状况的临床价值。目前关于非小细胞肺癌的临床研究主要应用AJCC分期 [<xref ref-type="bibr" rid="hanspub.35865-ref5">5</xref>]，根据其规定发生远处转移即为IV期，无远处转移的局部晚期为III期(包括IIIA、B、C期)。Kazushi [<xref ref-type="bibr" rid="hanspub.35865-ref6">6</xref>] 等EGFR突变型晚期NSCLC患者的临床资料进行回顾性研究，IIIB期患者125人，IV期患者1105人。发现临床分期是EGFR-TKI治疗EGFR突变型晚期NSCLC患者PFS和OS独立影响因素，并且IIIB期患者较IV期患者应用EGFR-TKI的疗效更好。Minami [<xref ref-type="bibr" rid="hanspub.35865-ref7">7</xref>] 也得出了相似的结论。本研究分析了71例EGFR突变的晚期NSCLC患者的临床资料后发现：III期和IV期患者的中位PFS分别为16和8.5个月，发现临床分期为IV期是该类患者预后的独立危险因素。</p><p>血小板水平对恶性肿瘤细胞的增殖与转移等密切相关。相关研究指出 [<xref ref-type="bibr" rid="hanspub.35865-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.35865-ref9">9</xref>]，血小板升高在恶性肿瘤患者中十分常见。本研究单因素分析结果提示血小板水平与应用EGFR-TKI治疗的EGFR突变型NSCLC的PFS相关并有统计学意义(P = 0.017)，而多因素分析无统计学意义(P = 0.061)，说明治疗前血小板水平与应用EGFR-TKI治疗的EGFR突变型晚期NSCLC患者的预后相关，但并不是这类患者预后的独立影响因素。</p><p>恶性肿瘤的炎症微环境反映了肿瘤细胞、人体的免疫系统和炎症反应三者间的关系。相关研究 [<xref ref-type="bibr" rid="hanspub.35865-ref10">10</xref>] 表明，肿瘤的增殖、血管过度生成以及肿瘤发生远处转移，会依赖炎症反应产生的炎症介质、CRP和诱导免疫细胞来完成。本研究回顾性分析71例应用EGFR-TKI治疗的晚期非小细胞肺癌患者的临床数据，结果示治疗前外周血淋巴细胞计数与该类患者服用EGFR-TKI的PFS相关(P &lt; 0.001)；多因素分析提示外周血淋巴细胞计数&lt;1.1 &#215; 10<sup>9</sup>/L是这类患者PFS的独立危险因素(HR = 0.565, 95% CI: 0.290~0.744; P &lt; 0.001)。有研究 [<xref ref-type="bibr" rid="hanspub.35865-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.35865-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.35865-ref13">13</xref>] 指出炎症反应和肿瘤患者预后相关。而炎症反应、免疫状况和营养状况三者本身密切联系，并且三者均与肿瘤患者预后相关。所以，我们研究SII/ALB与EGFR-TKI治疗的EGFR突变型晚期NSCLC患者预后的相关性。通过Cox单因素分析，发现治疗前SII/ALB与EGFR-TKI治疗晚期非小细胞肺癌患者的PFS具有相关性(P &lt; 0.001)；Cox多因素分析显示治疗前SII/ALB值&#179;18.30是应用EGFR-TKI治疗的EGFR突变型晚期非小细胞肺癌患者预后的独立危险因素(HR = 2.472, 95% CI: 1.055~5.788; P = 0.037)，与不良预后相关。</p><p>应用EGFR-TKI治疗前的SII/ALB值可以综合反映EGFR突变型晚期非小细胞肺癌患者当时的营养状况、炎症反应和免疫状况，并且SII/ALB计算方法简便，所需临床数据均可从患者住院的常规检查中获得。本研究得出EGFR-TKI治疗前的高SII/ALB值预示着应用EGFR-TKI治疗的晚期非小细胞肺癌患者的预后较差。所以，对于治疗前SII/ALB值较高的EGFR突变型晚期非小细胞肺癌患者，应该由临床医生判断其对EGFR-TKI可能的获益程度及预后情况，并及时调整治疗方案，使患者最大获益。随着相关研究的不断深入，相信会有更多预测准确、成本小、便于分析的标志物被人们发现。</p></sec><sec id="s7"><title>文章引用</title><p>王梓聿,李 玲,袁胜利. SII/ALB与EGFR基因突变型晚期非小细胞肺癌预后的相关性分析Correlation between SII/ALB and the Prognosis of EGFR Gene Mutation in Advanced Non-Small Cell Lung Cancer[J]. 临床医学进展, 2020, 10(06): 857-863. https://doi.org/10.12677/ACM.2020.106131</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.35865-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ferlay, J., Colombet, M. and Soerjomataram, I. (2019) Estimating the Global Cancer Incidence and Mortality in 2018: GLOBOCAN Sources and Methods. International Journal of Cancer, 144, 1941-1953.  
&lt;br&gt;https://doi.org/10.1002/ijc.31937</mixed-citation></ref><ref id="hanspub.35865-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Schulze, A.B., Evers, G., Kerkhoff, A., et al. (2019) Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer. Cancers (Basel), 11, 3-13. &lt;br&gt;https://doi.org/10.3390/cancers11050690</mixed-citation></ref><ref id="hanspub.35865-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Jemal, A., Siegel, R., Ward, E., et al. (2009) Cancer Statistics. CA: A Cancer Journal for Clinicians, 59, 225-249.  
&lt;br&gt;https://doi.org/10.3322/caac.20006</mixed-citation></ref><ref id="hanspub.35865-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">姜源. SII/ALB对小细胞肺癌患者的临床预后价值[D]: [硕士学位论文]. 山东: 青岛大学医学部, 2019: 1-18.</mixed-citation></ref><ref id="hanspub.35865-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Abdel-Rahman, O. (2017) Impact of the Staging Method on the Prognostic Utility of the 8th AJCC Staging System for Non-Small Cell Lung Cancer. Future Oncology, 25, 2277-2284. &lt;br&gt;https://doi.org/10.2217/fon-2017-0248</mixed-citation></ref><ref id="hanspub.35865-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Inoue, A., Yoshida, K., Morita, S., et al. (2016) Characteristics and Overall Survival of EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors: A Retrospective Analysis for 1660 Japanese Patients. Japanese Journal of Clinical Oncology, 46, 462-467. &lt;br&gt;https://doi.org/10.1093/jjco/hyw014</mixed-citation></ref><ref id="hanspub.35865-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Minami, S., Ogata, Y., Ihara, S., Yamamoto, S. and Komuta, K. (2017) Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor. World Journal of Oncology, 8, 180-187. &lt;br&gt;https://doi.org/10.14740/wjon1069w</mixed-citation></ref><ref id="hanspub.35865-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Dupré, A. and Malik, H.Z. (2018) Inflammation and Cancer: What a Surgical Oncologist Should Know. European Journal of Surgical Oncology, 44, 566-570. &lt;br&gt;https://doi.org/10.1016/j.ejso.2018.02.209</mixed-citation></ref><ref id="hanspub.35865-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Lai, Q., Melandro, F., Larghi Laureiro, Z., et al. (2018) Platelet-to-Lymphocyte Ratio in the Setting of Liver Transplantation for Hepatocellular Cancer: A Systematic Review and Meta-Analysis. World Journal of Gastroenterology, 24, 1658-1665. &lt;br&gt;https://doi.org/10.3748/wjg.v24.i15.1658</mixed-citation></ref><ref id="hanspub.35865-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Mantovani, A., Allavena, P. and Sica, A. (2008) Cancer-Related Inflammation. Nature, 454, 436-444.  
&lt;br&gt;https://doi.org/10.1038/nature07205</mixed-citation></ref><ref id="hanspub.35865-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Shao, N. and Cai, Q. (2015) High Pretreatment Serum C-Reactive Protein Level Predicts a Poor Prognosis for Combined Small-Cell Lung Cancer. Tumor Biology, 36, 8465-8470. &lt;br&gt;https://doi.org/10.1007/s13277-015-3611-z</mixed-citation></ref><ref id="hanspub.35865-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">李娟, 黄沈珺, 潘月龙, 孟庆莲. 晚期肿瘤患者营养状况检测指标的研究[J]. 重庆医学, 2015, 44(35): 4953-4957.</mixed-citation></ref><ref id="hanspub.35865-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">孙成, 田志刚. 免疫评分: 依据肿瘤组织免疫特性进行预后预测[J]. 中国肿瘤生物治疗杂志, 2015, 22(2): 177-181.</mixed-citation></ref></ref-list></back></article>